Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15872041 | 0.98 | HRH3 (0.54) | HRH3ALDH1A1KDM4ETDP1GAA | |
| SCHEMBL4520045 | 0.88 | ALDH1A1 (0.52) | HRH3ALDH1A1KDM4ETDP1GAA | |
| SCHEMBL8059080 | 0.87 | ALDH1A1 (0.56) | HRH3ALDH1A1KDM4ETDP1GAA | |
| SCHEMBL15587428 | 0.84 | ALDH1A1 (0.54) | HRH3ALDH1A1KDM4ETDP1GAA | |
| SCHEMBL13960087 | 0.82 | ALDH1A1 (0.60) | HRH3ALDH1A1KDM4ETDP1GAA | |
| SCHEMBL21968513 | 0.81 | KDM4E (0.47) | HRH3ALDH1A1KDM4ETDP1GAA | |
| SCHEMBL26114519 | 0.81 | MEN1 (0.42) | ALDH1A1KDM4ETDP1POLBHTT | |
| SCHEMBL18753614 | 0.81 | LMNA (0.58) | ALDH1A1KDM4EGAASMN1; SMN2POLB | |
| SCHEMBL12854 | 0.80 | HRH3 (0.67) | HRH3ALDH1A1KDM4ETDP1GAA | |
| SCHEMBL29447423 | 0.80 | HRH3 (0.67) | HRH3ALDH1A1KDM4ETDP1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321067-A1 | DOSING REGIMEN COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2023-10-12 | — | — | US | disclosed |
| US-11299490-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2022-04-12 | — | — | US | disclosed |
| WO-2010067233-A1 | 1,2,4 TRIAZOLO [4, 3 -A] [1,5] BENZODIAZEPIN-5 (6H) -ONES AS AGONISTS OF THE CHOLECYSTOKININ-1 RECEPTOR (CCK-IR) | PFIZER INC. (US) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321067-A1 | DOSING REGIMEN COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | IKZF1, IKZF2, IKZF3 | HRH3 4828/4885ALDH1A1 2551/4885KDM4E 335/4885 |
| US-11299490-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | SCN1A, SCN1B, SCN2B | HRH3 1685/4885ALDH1A1 2797/4885KDM4E 1252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.